These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 80691)

  • 1. Should renal-transplant patients be screened for C.M.V.?
    Lancet; 1978 Oct; 2(8093):770-1. PubMed ID: 80691
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytomegalovirus vaccination and renal transplantation.
    Glazer JP; Friedman HM; Grossman RA; Barker CF; Starr SE; Plotkin SA
    Lancet; 1978 Jan; 1(8055):90-1. PubMed ID: 74583
    [No Abstract]   [Full Text] [Related]  

  • 3. Cytomegalovirus vaccine in renal transplant candidates: progress report of a randomized, placebo-controlled, double-blind trial.
    Balfour HH; Sachs GW; Welo P; Gehrz RC; Simmons RL; Najarian JS
    Birth Defects Orig Artic Ser; 1984; 20(1):289-304. PubMed ID: 6329368
    [No Abstract]   [Full Text] [Related]  

  • 4. Prevention of cytomegalovirus disease by Towne strain live attenuated vaccine.
    Plotkin SA; Smiley ML; Friedman HM; Starr SE; Fleisher GR; Wlodaver C; Dafoe DC; Friedman AD; Grossman RA; Barker CF
    Birth Defects Orig Artic Ser; 1984; 20(1):271-87. PubMed ID: 6329367
    [No Abstract]   [Full Text] [Related]  

  • 5. Cytomegalovirus vaccine in renal transplants.
    Betts RF
    Ann Intern Med; 1979 Nov; 91(5):780-2. PubMed ID: 227302
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytomegalovirus immune globulin in renal-transplant recipients.
    N Engl J Med; 1988 Apr; 318(16):1065-7. PubMed ID: 2832759
    [No Abstract]   [Full Text] [Related]  

  • 7. Live cytomegalovirus vaccination of renal transplant candidates. A preliminary trial.
    Glazer JP; Friedman HM; Grossman RA; Starr SE; Barker CF; Perloff LJ; Huang ES; Plotkin SA
    Ann Intern Med; 1979 Nov; 91(5):676-83. PubMed ID: 227299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus vaccine virus (Towne strain) does not induce latency.
    Plotkin SA; Huang ES
    J Infect Dis; 1985 Aug; 152(2):395-7. PubMed ID: 2993436
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevention of cytomegalovirus disease following renal transplantation.
    Hanshaw JB
    Am J Dis Child; 1977 Aug; 131(8):841-5. PubMed ID: 196502
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-CMV hyperimmune globulin prophylaxis does not prevent CMV disease in CMV-negative renal transplant patients.
    Pakkala S; Salmela K; Lautenschlager I; Ahonen J; Häyry P
    Transplant Proc; 1992 Feb; 24(1):283-4. PubMed ID: 1311472
    [No Abstract]   [Full Text] [Related]  

  • 11. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients.
    Plotkin SA; Higgins R; Kurtz JB; Morris PJ; Campbell DA; Shope TC; Spector SA; Dankner WM
    Transplantation; 1994 Dec; 58(11):1176-8. PubMed ID: 7992358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship of epidemiology and treatment factors to infection and allograft survival in renal transplantation.
    Betts RF
    Birth Defects Orig Artic Ser; 1984; 20(1):87-99. PubMed ID: 6329375
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytomegalovirus immune globulin.
    Med Lett Drugs Ther; 1988 Oct; 30(777):100. PubMed ID: 2845236
    [No Abstract]   [Full Text] [Related]  

  • 14. Rapid diagnosis of cytomegalovirus infection in renal transplant recipients.
    Lautenschlager I; Suni J; Ahonen J; Grönhagen-Riska C; Räisänen S; Tukiainen P
    Transplant Proc; 1988 Jun; 20(3):408-9. PubMed ID: 2837851
    [No Abstract]   [Full Text] [Related]  

  • 15. Four-year experience with exclusive use of cytomegalovirus antibody (CMV-Ab)-negative donors for CMV-Ab-negative kidney recipients.
    Ackermann JR; LeFor WM; Weinstein S; Kahana L; Shires DL; Tardif G; Baxter J
    Transplant Proc; 1988 Feb; 20(1 Suppl 1):469-71. PubMed ID: 2831644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections.
    Cheeseman SH; Rubin RH; Stewart JA; Tolkoff-Rubin NE; Cosimi AB; Cantell K; Gilbert J; Winkle S; Herrin JT; Black PH; Russell PS; Hirsch MS
    N Engl J Med; 1979 Jun; 300(24):1345-9. PubMed ID: 220536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus infections in transplant patients: methods of prevention of primary cytomegalovirus.
    Bowden RA
    Transplant Proc; 1991 Jun; 23(3 Suppl 3):136-8, discussion 138. PubMed ID: 1648818
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevention of cytomegalovirus disease in transplant recipients.
    Pidgeon GB; Bailey RR
    N Z Med J; 1993 Nov; 106(967):468-9. PubMed ID: 8233192
    [No Abstract]   [Full Text] [Related]  

  • 19. Ganciclovir for cytomegalovirus infection in renal transplant recipients.
    Lancet; 1989 Jan; 1(8631):216-7. PubMed ID: 2563118
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.